SSG
TXG icon

Summit Securities Group’s 10x Genomics TXG Stock Holding History

Summit Securities Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-684
Closed -$8K – 1260
2025
Q3 		$8K Buy
+684
New +$8.92K ﹤0.01% 888
2025
Q1 		– Sell
-489
Closed -$7.02K – 1110
2024
Q4 		$7.02K Buy
+489
New +$7.72K ﹤0.01% 493
2023
Q4 		– Sell
-583
Closed -$24K – 922
2023
Q3 		$24K Buy
+583
New +$30.3K ﹤0.01% 349
2022
Q2 		– Sell
-6
Closed – – 1225
2022
Q1 		$0 Buy
+6
New +$525 ﹤0.01% 1365

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Securities Group's TXG Position: Q4 2025 in Review

Summit Securities Group sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 684 shares — an estimated $8K sold.

Summit Securities Group first reported a position in TXG in Q1 2022 and held it in 4 quarters. The position peaked at $24K in Q3 2023. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Summit Securities Group reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Summit Securities Group sold 684 10x Genomics shares in Q4 2025, an estimated $8K.
  • Summit Securities Group first reported a position in 10x Genomics in Q1 2022 and held it in 4 quarters.
  • Summit Securities Group's 10x Genomics position peaked at $24K in Q3 2023.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Summit Securities Group's 13F filing for Q4 2025, filed 17 Feb 2026.